Overview
STATEMENT OF NEED
Bladder cancer is the sixth most common malignancy among adults in the United States. Approximately 80,470 new cases are diagnosed annually and 17,670 people die of the disease. More than 90% of patients with bladder cancer have the urothelial carcinoma subtype, which has a high rate of recurrence whether it is low or high grade. Approximately half of all bladder cancers are diagnosed in situ, for which the 5-year relative survival rate is 95%. For tumors diagnosed as a localized, regional, or distant stage, the 5-year survival rate declines to 69%, 35%, and 5%, respectively.
TARGET AUDIENCE
Military, academic, and private practice urologists and other health care professionals involved in the treatment of patients with urothelial carcinoma.
LEARNING OBJECTIVES
- Evaluate patient- and tumor-related factors that can inform personalized care plans for patients with urothelial carcinoma
- Differentiate the mechanism of action of novel therapies for locally advanced/metastatic urothelial carcinoma
- Assess emerging clinical evidence on novel treatment approaches for patients with locally advanced/metastatic urothelial carcinoma, including those ineligible for cisplatin-based chemotherapy
FACULTY
Arjun V. Balar, MD (Chairperson)
Assistant Professor of Medicine
NYU Langone Health
REGISTRATION
There is no fee to participate in or claim CME credit for this activity.
Co-provided by
Physicians
USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
USF Health designates this activity for a maximum of 0.75 AMA PRA Category 1 Credits™.
Physician Assistants
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 0.75 hours of Category 1 credit for completing this program.
Nurse Practitioners
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
ONCC RECERTIFICATION
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.
OCN®, CPHON®, CBCN®, AOCNP®, AOCNS®, and BMTCN® renewal candidates may apply 0.5 ILNA points toward:
- Diagnosis and Staging
- Cancer Continuum
- Oncology Nursing Practice
- Survivorship
- Symptom Management
- Treatment
Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of CNE awarded from this course.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS
USF Health and i3 Health endorse the standards of the ACCME that require everyone in a position to control the content of a CME activity to disclose all financial relationships with commercial interests that are related to the content of the CME activity. CME activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
USF Health and i3 Health will identify, review, and resolve all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. USF Health and i3 Health do not endorse any products or services.
Relevant financial relationships exist between the following individuals and commercial interests:
Arjun V. Balar, MD, discloses that he has served as a consultant for AstraZeneca/MedImmune, Genentech, Incyte, Janssen, Merck, Nektar, Pfizer, and Seattle Genetics. He has received research support from AstraZeneca/MedImmune, Genentech, Immunomedics, Merck, Nektar, and Seattle Genetics. Dr. Balar has served as a speaker for AstraZeneca/MedImmune, Genentech, and Merck. He has also served on the steering committee for Merck and Nektar.
USF Health OCPD staff members have no relevant financial relationships to disclose.
The i3 Health planners, reviewers, and managers have nothing to disclose.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must:
- Take the pretest
- Watch the video
- Pass the posttest with a score of ≥80%
- Complete the activity evaluation
- Download or print their Certificate of Credit
UNAPPROVED USE DISCLOSURE
USF Health and i3 Health require CME faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.
This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
DISCLAIMER
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
COMMERCIAL SUPPORT
This activity is supported by an independent educational grant from Merck.
Aggregate participant data will be shared with commercial supporters of this activity.
CONTACT INFORMATION
Technical queries or questions regarding activity credit should be directed to i3 Health at This email address is being protected from spambots. You need JavaScript enabled to view it..